Study guide
2.2 Conservative Management, Non-Pharmacologic & Pharmacologic Therapies for OA
ONCB Orthopaedic Nurse Certified ONC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: ONC Exam Overview, Core Nursing Foundations & Neurovascular Assessment
1.1 ONC Certification Framework, Exam Blueprint & Test Strategies 1.2 Comprehensive Musculoskeletal Assessment & Diagnostic Modalities 1.3 Neurovascular Assessment & Orthopaedic Physical Examination Techniques
2 Chapter 2: Degenerative Joint Disease & Osteoarthritis Management
2.1 Osteoarthritis Pathophysiology, Risk Factors & Clinical Phenotypes 2.2 Conservative Management, Non-Pharmacologic & Pharmacologic Therapies for OA 2.3 Intra-Articular Injections & Joint Preservation Interventions
3 Chapter 3: Total Joint Arthroplasty — Hip & Knee
3.1 Total Hip Arthroplasty (THA): Surgical Approaches, Biomechanics & Component Types 3.2 Total Hip Arthroplasty: Postoperative Management, Hip Precautions & Dislocation Prevention 3.3 Total Knee Arthroplasty (TKA): Indications, Implant Designs & Surgical Techniques 3.4 Total Knee Arthroplasty: Postoperative Nursing Care, Pain Management & Early Mobilization
4 Chapter 4: Shoulder & Upper/Lower Extremity Arthroplasty and Revision Surgery
4.1 Total Shoulder Arthroplasty (TSA): Anatomic vs. Reverse TSA Indications & Precautions 4.2 Ankle, Elbow & Wrist Arthroplasty: Indications, Nursing Management & Functional Outcomes 4.3 Revision Arthroplasty, Aseptic Loosening, Osteolysis & Implant Failure
5 Chapter 5: Spinal Degenerative Disorders & Spinal Surgery
5.1 Cervical & Lumbar Spondylosis, Degenerative Disc Disease & Herniation 5.2 Spinal Stenosis, Neurogenic Claudication & Spondylolisthesis 5.3 Surgical Interventions: ACDF, Posterior Cervical Decompression, Lumbar Laminectomy & Fusion 5.4 Postoperative Spinal Nursing Care, CSF Leak Detection & Log-Rolling Protocols
6 Chapter 6: Orthopaedic Trauma: Fracture Mechanics, Classification & Healing
6.1 Fracture Mechanics, Morphology & AO/OTA Classification Principles 6.2 Open Fracture Management & Gustilo-Anderson Classification Protocol 6.3 Biology of Bone Healing, Physis (Salter-Harris) Injuries & Healing Complications
7 Chapter 7: Orthopaedic Emergencies & Trauma Complications
7.1 Acute Compartment Syndrome: Pathophysiology, The 6 Ps, Pressure Monitoring & Fasciotomy 7.2 Fat Embolism Syndrome (FES): Pathophysiology, Triad Recognition & Supportive Care 7.3 Hemorrhagic Shock, Pelvic Ring Disruptions & Damage Control Orthopaedics 7.4 Traumatic Spinal Cord Injury (SCI), Spinal/Neurogenic Shock & Autonomic Dysreflexia
8 Chapter 8: Upper Extremity, Lower Extremity & Pelvic Trauma Nursing Care
8.1 Proximal Femur & Hip Fractures: Femoral Neck, Intertrochanteric & Subtrochanteric Fixation 8.2 Diaphyseal & Articular Fractures of the Lower Extremity (Femur, Tibia, Ankle & Foot) 8.3 Upper Extremity Fractures, Dislocation Management & Peripheral Nerve Injuries
9 Chapter 9: Casts, Splints, Traction & External Fixation
9.1 Plaster & Synthetic Casting: Application, Cast Care, Windowing & Bivalving 9.2 Skin & Skeletal Traction: Buck's, Russell's, Balanced Suspension & Skeletal Traction Protocols 9.3 External Fixation, Ring Fixators, Pin Site Care Protocols & Infection Surveillance
10 Chapter 10: Sports Injuries: Ligamentous, Meniscal & Soft-Tissue Pathologies
10.1 Knee Ligamentous Injuries: ACL, PCL, MCL & LCL Pathophysiology, Special Tests & Reconstruction 10.2 Meniscal Pathologies: Vascular Zones, Tear Patterns, Meniscectomy vs. Meniscal Repair 10.3 Shoulder Instability, Labral Lesions (SLAP/Bankart) & Rotator Cuff Disorders 10.4 Tendinopathies, Overuse Syndromes, Concussion Protocol & Return-to-Play Criteria
11 Chapter 11: Metabolic Bone Disorders & Fragility Fractures
11.1 Osteoporosis & Osteopenia: Bone Remodeling, Risk Factors & DEXA Diagnostics 11.2 Pharmacotherapy: Bisphosphonates, Denosumab, Anabolic Agents & Patient Education 11.3 Osteomalacia, Rickets & Paget's Disease of Bone (Osteitis Deformans) 11.4 Vertebral Compression Fractures: Pathogenesis, Bracing, Vertebroplasty & Kyphoplasty
12 Chapter 12: Inflammatory Musculoskeletal Disorders & Infectious Conditions
12.1 Rheumatoid Arthritis: Autoimmune Pathophysiology, Manifestations & DMARD / Biologic Therapies 12.2 Ankylosing Spondylitis, Psoriatic Arthritis, Gout & Pseudogout (CPPD) 12.3 Septic Arthritis: Microorganisms, Arthrocentesis Findings, Emergency Debridement & Nursing Care 12.4 Osteomyelitis: Acute vs. Chronic, Biofilm Dynamics, Surgical Debridement & Long-Term Antibiotic Care
13 Chapter 13: Congenital, Pediatric & Musculoskeletal Oncologic Conditions
13.1 Developmental Dysplasia of the Hip (DDH), Clubfoot (Talipes Equinovarus) & Pediatric Hip Disorders 13.2 Pediatric & Adolescent Spinal Deformities: Idiopathic Scoliosis, Kyphosis & Bracing / Surgery 13.3 Musculoskeletal Oncology: Benign Bone Tumors, Primary Malignancies & Metastatic Bone Disease
14 Chapter 14: Neuromuscular Syndromes, Pain Modalities & Rehabilitation Competencies
14.1 Peripheral Nerve Compression Neuropathies (CTS, Cubital Tunnel, Tarsal Tunnel) & Complex Regional Pain Syndrome 14.2 Multimodal Pharmacologic Analgesia, Regional Nerve Blocks, PCA Management & Opioid Stewardship 14.3 Progressive Ambulation, Assistive Device Prescriptions, Crutch Gaits, DVT Prophylaxis & Discharge Planning
2.2 Conservative Management, Non-Pharmacologic & Pharmacologic Therapies for OA
Key Takeaways Explain This Topic AI
Non-pharmacologic interventions form the mandatory cornerstone of first-line osteoarthritis management, incorporating weight loss (targeting ≥5% to 10% total body mass reduction), structured low-impact aerobic exercise, aquatic therapy, and targeted muscle strengthening.
Topical NSAIDs (e.g., diclofenac sodium 1% gel or 1.3% patch) are the guideline-recommended first-line pharmacotherapy for superficial joints such as the knee and hand, delivering equivalent analgesia to oral NSAIDs with only 1% to 10% systemic bioavailability.
Oral NSAID therapy requires rigorous multi-system risk stratification; patients with elevated gastrointestinal risk require COX-2 selective inhibitors (celecoxib) or non-selective NSAIDs co-prescribed with a proton pump inhibitor (PPI).
Acetaminophen (paracetamol) provides minimal, clinically non-meaningful pain reduction in OA and carries significant hepatotoxicity risks above 3 g/day, whereas duloxetine provides effective central pain modulation for nociplastic pain mechanisms.
Chronic oral opioid therapy is strongly recommended against in osteoarthritis guidelines due to substantial risks of physical dependence, tolerance, fall-related fractures, and lack of sustained long-term functional efficacy.
Last updated: August 2026
2.2 Conservative Management, Non-Pharmacologic & Pharmacologic Therapies for OA
Core Practice Guideline: Both the American Academy of Orthopaedic Surgeons (AAOS) and the American College of Rheumatology (ACR) establish that non-pharmacologic modalities must be initiated as the foundational baseline for all patients with osteoarthritis. Pharmacologic agents are introduced in a tiered, risk-stratified manner to supplement lifestyle and physical interventions, prioritizing localized topical agents before advancing to systemic oral medications.
Evidence-Based Non-Pharmacologic Foundations
Non-pharmacologic interventions modify joint biomechanics, enhance periarticular dynamic stability, and mitigate systemic inflammatory drivers. Multimodal Non-Pharmacologic Management Strategy
- ├── Biomechanical Unloading
- │ ├── Weight Loss: Target ≥5% to 10% total body weight reduction
- │ ├── Contralateral Cane Ambulation: Offloads joint contact force by ~50%
- │ └── Compartmental Unloader Bracing: Corrects varus/valgus coronal malalignment
- ├── Physical & Aquatic Conditioning
- │ ├── Low-Impact Aerobic Exercise (Cycling, Walking, Elliptical)
- │ ├── Aquatic Therapy (Buoyancy unloads 50% to 90% of gravitational weight)
- │ └── Resistance Training (Quadriceps & Hamstrings Isometrics / Closed-Chain Exercises)
- └── Biomechanical Orthotics
- ├── Lateral Wedge Insoles (for medial compartment OA with mild varus)
- └── Hand Splinting (1st CMC immobilization during painful exacerbations)
- 1. Weight Loss Biomechanics
In weight-bearing joints, especially the knee and hip, reducing body weight yields exponential reductions in joint compressive stress. During normal level walking, every 1 pound of weight loss removes approximately 4 pounds of compressive force from the tibiofemoral joint per stride. Across an average 5,000-step day, a 10-pound weight reduction eliminates 200,000 pounds (100 tons) of cumulative mechanical load. Achieving a ≥5% to 10% weight loss significantly improves Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and physical function scores.
2. Exercise & Aquatic Therapy Protocols
Aquatic Therapy: Immersion to the xiphoid process unloads approximately 60% to 75% of body weight, and immersion to the neck unloads 90%. This permits active range of motion and resistive muscle strengthening without provocative joint impaction.
Low-Impact Aerobic & Resistance Conditioning: Enhances synovial fluid circulation and cartilage nutrition through cyclic imbibition. Quadriceps strengthening is paramount; quadriceps weakness is an independent, modifiable risk factor for accelerated knee cartilage degeneration.
Assistive Device Education (Contralateral Cane): When using a single-point cane, patients must hold the cane in the hand contralateral (opposite) to the affected lower extremity . Advancing the cane simultaneously with the affected limb broadens the base of support and reduces the required abductor muscle force (gluteus medius/minimus), lowering the resultant hip and knee joint reaction force by up to 50% .
Stepwise Pharmacologic Ladder & Topical NSAIDs
When non-pharmacologic modalities provide incomplete symptom control, pharmacotherapy is layered in a stepwise, risk-stratified sequence: Pharmacologic Treatment Hierarchy for Osteoarthritis
- [Step 1: First-Line Topical Agents] ──── Diclofenac Sodium 1% Gel / 1.3% Patch / Capsaicin
- │
- [Step 2: Risk-Stratified Oral NSAIDs] ── Oral NSAID (Lowest Dose, Shortest Duration)
- │ + PPI Gastroprotection or COX-2 Selective (Celecoxib)
- [Step 3: Central Pain Modulator] ─────── Duloxetine (SNRI for central sensitization / nociplastic pain)
- │
- [Avoided / Highly Restricted] ───────── Chronic Oral Opioids (Contraindicated for routine management)
- Topical NSAIDs: The Guideline-Preferred First-Line Agent
Topical NSAIDs, such as diclofenac sodium 1% gel or diclofenac 1.3% transdermal patch , are strongly recommended over oral NSAIDs as initial pharmacotherapy for knee and superficial joint OA.
Mechanism & Pharmacokinetics: Topical diclofenac penetrates through the skin into the subcutaneous tissue, synovial fluid, and articular cartilage, exerting local anti-inflammatory effects via cyclooxygenase inhibition. Systemic bioavailability is only 1% to 10% of an equivalent oral dose.
Clinical Efficacy & Safety: Achieves pain relief equivalent to oral NSAIDs while dramatically minimizing systemic gastrointestinal, renal, and cardiovascular adverse events.
Nursing Administration Points:
Use the manufacturer-provided dosing card (2 g for upper extremity joints; 4 g for lower extremity joints like the knee).
Do not apply to open wounds, infected skin, or concurrently with other oral NSAIDs without provider clearance.
Avoid applying external heat sources (e.g., heating pads) over topical patches or gel, which dramatically accelerates systemic absorption.
Oral NSAID Selection, COX Selectivity & Organ System Toxicity
Oral nonsteroidal anti-inflammatory drugs inhibit the cyclooxygenase enzymes ( COX-1 and COX-2 ), blocking the conversion of arachidonic acid to pro-inflammatory prostaglandins:
Organ System Pathophysiologic Risk Mechanism High-Risk Patient Populations Preventive & Nursing Management
Gastrointestinal (GI) Non-selective NSAIDs inhibit COX-1-mediated synthesis of cytoprotective prostaglandins ( PGE2 , PGI2 ), impairing gastric mucus secretion, mucosal blood flow, and bicarbonate barrier, leading to ulceration and bleeding. Age >65 years, history of peptic ulcer disease (PUD) or upper GI bleeding, high-dose/concurrent NSAID use, concurrent anticoagulants or systemic corticosteroids. Prescribe a COX-2 selective inhibitor (Celecoxib) OR a non-selective NSAID co-prescribed with a Proton Pump Inhibitor (PPI, e.g., omeprazole) or misoprostol.
Cardiovascular (CV) Inhibition of vascular endothelial COX-2 reduces prostacyclin (vasodilator and platelet inhibitor) while platelet COX-1 synthesis of thromboxane A2 (vasoconstrictor and platelet aggregator) remains active, promoting thrombosis, sodium retention, and hypertension. Pre-existing coronary artery disease (CAD), congestive heart failure (CHF), uncontrolled hypertension, prior myocardial infarction (MI) or stroke. Use lowest effective dose for shortest duration; Naproxen exhibits the most favorable cardiovascular safety profile among non-selective NSAIDs. Avoid NSAIDs in severe CHF.
Renal Inhibition of vasodilatory prostaglandins (PGE2, PGI2) in the renal vasculature reduces renal blood flow and glomerular filtration rate (GFR), causing sodium/water retention, peripheral edema, and acute tubular injury. Chronic kidney disease (CKD, eGFR <60 mL/min), hypovolemia, CHF, cirrhosis, concurrent ACE inhibitors/ARBs/diuretics. Monitor serum creatinine, BUN, and potassium within 1 to 2 weeks of initiation. Avoid the "Triple Whammy" (NSAID + ACEI/ARB + Diuretic), which precipitously triggers acute kidney injury (AKI).
- Acetaminophen, Duloxetine & Central Pain Sensitization
- The Diminishing Role of Acetaminophen (Paracetamol)
Historically considered first-line for OA, contemporary meta-analyses (including Cochrane reviews and OARSI guidelines) demonstrate that acetaminophen has a clinically negligible effect size (standardized mean difference <0.2) in osteoarthritis pain reduction.
Safety Ceilings: Absolute maximum daily ceiling is 3,000 mg/day in healthy adults, and 2,000 mg/day in older adults, frail patients, or those with chronic alcohol use or mild-to-moderate hepatic impairment.
Nursing Surveillance: Educate patients to cross-check over-the-counter (OTC) combination cough/cold or sleep medications for hidden acetaminophen to prevent accidental hepatotoxicity.
Duloxetine: Targeting Nociplastic Pain & Central Sensitization
Chronic osteoarthritis often transitions from purely nociceptive joint pain to a state of central sensitization (augmented central pain processing, hyperalgesia, and impaired descending inhibitory pathways).
Mechanism of Action: Duloxetine (Cymbalta) is a Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) that potentates descending noradrenergic and serotonergic pain inhibitory pathways within the dorsal horn of the spinal cord.
Indications: Recommended by ACR guidelines as an effective adjunct for knee, hip, and multi-joint OA, particularly when NSAIDs are contraindicated (e.g., severe CKD, peptic ulcer disease, advanced heart failure) or when centralized pain features (widespread hypersensitivity, sleep disturbance) predominate.
Dosing & Nursing Monitoring: Initiated at 30 mg orally once daily for 1 week to minimize nausea, then titrated to a target dose of 60 mg daily. Monitor for dry mouth, constipation, dizziness, somnolence, and educate regarding the risk of serotonin syndrome when combined with other serotonergic medications.
Opioid Stewardship in Osteoarthritis
Major orthopaedic and rheumatology clinical practice guidelines ( AAOS, ACR, OARSI, CDC ) strongly advise against the routine prescription of chronic oral opioids (e.g., oxycodone, hydrocodone, morphine, tramadol) for osteoarthritis. Clinical Rationale Against Chronic Opioid Therapy in Osteoarthritis:
├── Lack of Long-Term Efficacy: No clinically meaningful functional improvement beyond 6-12 weeks
├── Neurobiological Risks: Rapid tolerance development, physical dependence, and Opioid-Induced Hyperalgesia (OIH)
├── Geriatric Vulnerabilities: Excessive sedation, cognitive blunting, constipation, urinary retention, respiratory depression
└── Orthopaedic Morbidities: 2- to 3-fold increase in fall risk, resulting in fragility fractures (femoral neck, spine)
Opioid administration in OA is restricted solely to short-term rescue (typically <3 to 7 days) during acute, severe, disabling flares when all first-line non-pharmacologic and non-opioid medications are strictly contraindicated, with a mandatory predefined exit and weaning strategy.